Chiahao Lu

Dr. Chiahao Lu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
CLChiahao Lu
Chiahao Lu
SHSommer Amundsen Huffmaster
Sommer Amundsen Huffmaster
PTPaul J. Tuite
Paul J. Tuite
JVJacqueline M. Vachon
Jacqueline M. Vachon
CMColum D. MacKinnon
Colum D. MacKinnon

1 September 2017 in Gait & Posture
Verified
Journal Article
Closed access
CLChiahao Lu
Chiahao Lu
SHSommer Amundsen Huffmaster
Sommer Amundsen Huffmaster
JHJack C. Harvey
Jack C. Harvey
CMColum D. MacKinnon
Colum D. MacKinnon

28 June 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
CLChiahao Lu
Chiahao Lu
SHSommer Amundsen Huffmaster
Sommer Amundsen Huffmaster
PTPaul J. Tuite
Paul J. Tuite
CMColum D. MacKinnon
Colum D. MacKinnon

15 November 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JAJoshua E. Aman
Joshua E. Aman
AAAviva Abosch
Aviva Abosch
MBMaggie Bebler
Maggie Bebler
CLChiahao Lu
Chiahao Lu
JUERGEN KONCZAKJUERGEN KONCZAK
JUERGEN KONCZAK

29 August 2023 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
CLChiahao Lu
Chiahao Lu
DKDhira Khosla
Dhira Khosla
AKAlexander Kent
Alexander Kent
HBHelen Bronte-Stewart
Helen Bronte-Stewart
KRKathryn H. Rosenbluth
Kathryn H. Rosenbluth
Background: Transcutaneous afferent patterned stimulation (TAPS) is a non-invasive neuromodulation therapy for the treatment of hand tremor in patients with essential tremor (ET). This retrospective post-market analysis evaluated the usage, effectiveness, and safety of TAPS in patients using TAPS beyond a 90-day trial period in a real-world setting. Methods: Study personnel screened a manufacturer’s database for TAPS devices that had been prescribed for the treatment of ET and used beyond a 90-day trial period between August 2019 and January 2023. The device logs were collected to extract the therapy usage, accelerometry measurements, and on-board ratings of tremor improvement. Study personnel also evaluated results of a voluntary survey requested by the manufacturer after the 90-day trial period. Adverse events were assessed from patients’ complaints reported to the manufacturer. Results: A total of 1,223 patients in the manufacturer’s database met the study criteria. The patients had used therapy between 90 and 1,233 days, with average usage of 5.6 sessions per week. Accelerometry data indicated 89% of patients experienced tremor improvement, with an average 64% improvement. 63% of patients rated at least half of their sessions as improved. No significant habituation was observed in patients who used therapy for more than one year. Approximately 62% of survey respondents either had reduced medication or planned to consult physicians about their medication usage. No serious safety events were reported, and 10% of patients reported minor safety complaints. Discussion: The analysis demonstrates the real-world effectiveness and safety of TAPS beyond a 90-day trial period over a longer timeframe and in a larger population size than previously published evidence.

26 January 2022 in Gait & Posture
Verified
Journal Article
Closed access
CLChiahao Lu
Chiahao Lu
KLKenneth H. Louie
Kenneth H. Louie
ETEmily L. Twedell
Emily L. Twedell
JVJerrold L. Vitek
Jerrold L. Vitek
CMColum D. MacKinnon
Colum D. MacKinnon
SCScott E. Cooper
Scott E. Cooper